The diabetes treatment devices market includes tools used to manage diabetes, such as insulin delivery systems (e.g., insulin pens, pumps, and jet injectors) as well as blood glucose monitoring devices (including self-monitoring meters and continuous glucose monitoring systems). This market supports individuals with diabetes—both Type 1 and Type 2—by enabling accurate glucose tracking and effective insulin therapy. Market growth is primarily driven by the rising global prevalence of diabetes and increased awareness of the importance of disease management. Significant innovations like smart insulin pens, automated/artificial pancreas systems, and app-connected devices are enhancing precision and easing daily management. North America leads the market thanks to high healthcare spending and technology adoption, while the Asia-Pacific region is emerging rapidly due to rising incidence rates and expanding healthcare access.
According to Fortune Business Insights, the global diabetes treatment devices market was valued at USD 10.83 billion in 2018 and is projected to reach USD 22.83 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period. In 2018, North America dominated the market with a 40.44% share.
In March 2021, F. Hoffmann-La Roche Ltd unveiled the Accu-Check Instant system, a cutting-edge blood glucose monitoring solution designed to support Roche’s integrated personalized diabetes management approach.
The market’s growth is propelled by multiple compelling forces. First and foremost is the rising prevalence of diabetes, notably the expanding pool of insulin-dependent type 1 patients, which amplifies demand for advanced insulin delivery devices. Additionally, technological advancements—from user-friendly insulin pens and self-monitored patch pumps to minimally invasive insulin delivery solutions—are reshaping patient experiences and driving adoption.
On the flip side, challenges such as high costs, regulatory hurdles, and supply chain complexities can restrain the pace of penetration—especially in lower-income regions (though these specifics come from the broader “Diabetes Care Devices” context, they reflect relevant headwinds).
The Fortune Business Insights report offers a comprehensive landscape of the market, including prevalence and incidence data, trends around insulin delivery advancements (like artificial pancreas systems), mergers and acquisitions, pricing dynamics, technological innovations, key industry trends, pricing analysis, and competitive strategies adopted by leading players.